How Will the Market React to AstraZeneca plc (AZN) Stock Getting a Bearish Rating

The market has been down on AstraZeneca plc (AZN) stock recently. AZN gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

AstraZeneca plc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on AZN!

See Full AZN Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With AZN Stock Today?

AstraZeneca plc (AZN) stock is trading at $64.72 as of 9:54 AM on Thursday, Mar 2, a drop of -$0.49, or -0.75% from the previous closing price of $65.21. The stock has traded between $64.25 and $64.77 so far today. Volume today is light. So far 405,937 shares have traded compared to average volume of 5,643,548 shares. To screen for more stocks like AstraZeneca plc click here.

More About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales. Click Here to get the full Stock Report for AstraZeneca plc stock.